Salidroside exerts anti-tumor effects in ovarian cancer by inhibiting STAT3/c-Myc pathway-mediated glycolysis
2024

Salidroside's Anti-Tumor Effects in Ovarian Cancer

Sample size: 8 publication 10 minutes Evidence: moderate

Author Information

Author(s): Yu Ge, Feng Xiaoling

Primary Institution: Harbin Medical University Cancer Hospital

Hypothesis

Does salidroside inhibit the malignant progression of ovarian cancer through the STAT3/c-Myc pathway?

Conclusion

Salidroside reduces ovarian cancer cell viability, migration, and invasiveness, induces apoptosis, and inhibits glycolysis by targeting the STAT3/c-Myc pathway.

Supporting Evidence

  • Salidroside treatment significantly decreased the viability of ovarian cancer cells.
  • Salidroside induced apoptosis in ovarian cancer cells.
  • Salidroside inhibited the migration and invasion of ovarian cancer cells.
  • Salidroside reduced glucose consumption and lactate production in ovarian cancer cells.
  • Salidroside inhibited the STAT3/c-Myc signaling pathway.

Takeaway

Salidroside is a natural compound that helps fight ovarian cancer by making cancer cells less able to grow and spread.

Methodology

The study used various assays including CCK-8, flow cytometry, and western blotting to assess the effects of salidroside on ovarian cancer cells.

Limitations

The study primarily focused on in vitro and animal models, which may not fully represent human responses.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.17305/bb.2024.10867

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication